Contraception - Pipeline Review, H2 2014

Published: Nov, 2014 | Pages: 99 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Contraception - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Contraception - Pipeline Review, H2 2014', provides an overview of the Contraception's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Contraception
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Contraception
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Contraception Overview 9
Therapeutics Development 10
Pipeline Products for Contraception - Overview 10
Pipeline Products for Contraception - Comparative Analysis 11
Contraception - Therapeutics under Development by Companies 12
Contraception - Therapeutics under Investigation by Universities/Institutes 14
Contraception - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Contraception - Products under Development by Companies 19
Contraception - Products under Investigation by Universities/Institutes 21
Contraception - Companies Involved in Therapeutics Development 22
Actavis plc 22
Adamis Pharmaceuticals Corporation 23
Agile Therapeutics, Inc. 24
ANI Pharmaceuticals, Inc. 25
Antares Pharma, Inc. 26
Bayer AG 27
Evofem, Inc. 28
HRA Pharma 29
Hydra Biosciences, Inc. 30
Intas Pharmaceuticals Ltd. 31
Ligand Pharmaceuticals, Inc. 32
Merck & Co., Inc. 33
Orbis Biosciences, Inc. 34
Pantarhei Bioscience BV 35
Teva Pharmaceutical Industries Limited 36
Contraception - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 46
(dehydroepiandrosterone + estradiol + progesterone) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
(desogestrel + ethinyl estradiol) - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
(estrogen + progesterone) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(ethinyl estradiol + levonorgestrel) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(gestodene + ethinyl estradiol) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
(levonorgestrel + ethinyl estradiol) - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
(nestorone + estradiol) - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
AG-200 ER - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AG-200 SP - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Amphora - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
C-31G - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
estrogen + progesterone - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
etonogestrel - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
etonogestrel Vaginal Ring - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
EVE-106 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
EVE-112 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
levonorgestrel - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
LJ-102 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
norethindrone - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
progesterone - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
progesterone - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
S-0101255 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule 1 for Fertility Control - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecule 2 for Fertility Control - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit CatSper Ion Channel for Contaception - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
tanaproget - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
ulipristal acetate - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
ulipristal acetate - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Contraception - Recent Pipeline Updates 82
Contraception - Dormant Projects 90
Contraception - Discontinued Products 91
Contraception - Product Development Milestones 92
Featured News & Press Releases 92
Nov 11, 2014: Afaxys Announces Wider National Availability of ella Emergency Contraceptive 92
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study 92
Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla(R) Phase 3 SECURE Study 93
Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla 93
Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion 94
Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date 95
Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device 95
Mar 31, 2014: HRA Pharma and Afaxys Join Forces on Emergency Contraceptive ella in the USA 95
Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora� Non-hormonal Contraceptive Gel 96
Jul 23, 2013: Enrollment Completed for Evofem's 3,200-subject Global Trial of Amphora Non-hormonal Contraceptive Gel 97
Appendix 98
Methodology 98
Coverage 98
Secondary Research 98
Primary Research 98
Expert Panel Validation 98
Contact Us 99
Disclaimer 99

List of Tables
Number of Products under Development for Contraception, H2 2014 10
Number of Products under Development for Contraception - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Number of Products under Investigation by Universities/Institutes, H2 2014 14
Comparative Analysis by Late Stage Development, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 16
Comparative Analysis by Early Stage Development, H2 2014 17
Comparative Analysis by Unknown Stage Development, H2 2014 18
Products under Development by Companies, H2 2014 19
Products under Development by Companies, H2 2014 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2014 21
Contraception - Pipeline by Actavis plc, H2 2014 22
Contraception - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 23
Contraception - Pipeline by Agile Therapeutics, Inc., H2 2014 24
Contraception - Pipeline by ANI Pharmaceuticals, Inc., H2 2014 25
Contraception - Pipeline by Antares Pharma, Inc., H2 2014 26
Contraception - Pipeline by Bayer AG, H2 2014 27
Contraception - Pipeline by Evofem, Inc., H2 2014 28
Contraception - Pipeline by HRA Pharma, H2 2014 29
Contraception - Pipeline by Hydra Biosciences, Inc., H2 2014 30
Contraception - Pipeline by Intas Pharmaceuticals Ltd., H2 2014 31
Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 32
Contraception - Pipeline by Merck & Co., Inc., H2 2014 33
Contraception - Pipeline by Orbis Biosciences, Inc., H2 2014 34
Contraception - Pipeline by Pantarhei Bioscience BV, H2 2014 35
Contraception - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 40
Number of Products by Stage and Mechanism of Action, H2 2014 42
Number of Products by Stage and Route of Administration, H2 2014 44
Number of Products by Stage and Molecule Type, H2 2014 45
Contraception Therapeutics - Recent Pipeline Updates, H2 2014 82
Contraception - Dormant Projects, H2 2014 90
Contraception - Discontinued Products, H2 2014 91